507 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
15
Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation.
Jagiellonian University Medical College
13
Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors.
Bristol Myers Squibb
1
Pregnane-10,2-carbolactones from a Hawaiian Marine Sponge in the Genus Myrmekioderma.
University of Hawaii At Manoa
16
Design, Synthesis, and Evaluation of Donepezil-Like Compounds as AChE and BACE-1 Inhibitors.
Magna Graecia University of Catanzaro
10
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.
Tu Dortmund University
4
Tasiamide F, a potent inhibitor of cathepsins D and E from a marine cyanobacterium.
University of Florida
9
Fragment-Linking Approach Using (19)F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors ofß-Secretase.
Amgen
14
Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aß Reduction in Rodents.
Bristol Myers Squibb
20
Structure-Based Design of an Iminoheterocyclicß-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aß in Nonhuman Primates.
Merck Research Laboratories
1
Design, synthesis and in vitro evaluation studies of sulfonyl-amino-acetamides as small molecule BACE-1 inhibitors.
Birla Institute of Technology
16
Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3ß Inhibitors.
University of Bologna
30
Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography.
China Pharmaceutical University
23
Synthesis of (3S,4S)-4-aminopyrrolidine-3-ol derivatives and biological evaluation for their BACE1 inhibitory activities.
Korea University of Science and Technology
1
Rational design, synthesis and in vitro evaluation of allylidene hydrazinecarboximidamide derivatives as BACE-1 inhibitors.
Birla Institute of Technology
15
1,4-Oxazineß-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads.
Janssen Pharmaceutica
31
Macrocyclic prolinyl acyl guanidines as inhibitors ofß-secretase (BACE).
Bristol Myers Squibb
15
Evaluation of transition-state mimics in a superior BACE1 cleavage sequence as peptide-mimetic BACE1 inhibitors.
Kyoto Pharmaceutical University
11
From AChE to BACE1 inhibitors: The role of the amine on the indanone scaffold.
University of Bologna
28
Transition state mimetics of the Plasmodium export element are potent inhibitors of Plasmepsin V from P. falciparum and P. vivax.
The Walter and Eliza Hall Institute of Medical Research
6
Peptidomimeticß-Secretase Inhibitors Comprising a Sequence of Amyloid-ß Peptide for Alzheimer's Disease.
Instituto De Biologia Experimental E Tecnol£Gica
15
Isolation of cholinesterase andß-secretase 1 inhibiting compounds from Lycopodiella cernua.
Catholic University of Daegu
7
Preparation and biological evaluation of conformationally constrained BACE1 inhibitors.
Eli Lilly
9
4,6-Diarylaminothiazines as BACE1 Inhibitors and Their Use for the Reduction of Beta-Amyloid Production.
Temple University
14
Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.
The Scripps Research Institute
12
Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.
Eurofarma Laboratorios
21
Design, synthesis and biological evaluation of tasiamide B derivatives as BACE1 inhibitors.
Fudan University
45
trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker.
Novartis Pharma
25
trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.
Novartis Pharma
16
Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitors.
Merck Research Laboratories
1
Novelß-amyloid aggregation inhibitors possessing a turn mimic.
Kobe Pharmaceutical University
19
An Orally Available BACE1 Inhibitor That Affords Robust CNS Aß Reduction without Cardiovascular Liabilities.
Amgen
21
Development of 2-aminooxazoline 3-azaxanthenes as orally efficaciousß-secretase inhibitors for the potential treatment of Alzheimer's disease.
Amgen
21
Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aß aggregation, andß-secretase.
Central China Normal University
20
Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors.
Novartis Institutes For Biomedical Research
15
Structure-based design, synthesis and biological evaluation of novelß-secretase inhibitors containing a pyrazole or thiazole moiety as the P3 ligand.
Purdue University
18
8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors.
Array Biopharma
36
Lead optimization and modulation of hERG activity in a series of aminooxazoline xantheneß-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
Amgen
18
Inhibitors ofß-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718).
Amgen
1
Dose-dependent inhibition of BACE-1 by the monoterpenoid 2,3,4,4-tetramethyl-5-methylenecyclopent-2-enone in cellular and mouse models of Alzheimer's disease.
University of Coimbra
9
ß-Secretase (BACE1)-inhibiting C-methylrotenoids from Abronia nana suspension cultures.
Kyungpook National University
9
Synthesis, characterization, and PK/PD studies of a series of spirocyclic pyranochromene BACE1 inhibitors.
Genentech
57
The evolution of amidine-based brain penetrant BACE1 inhibitors.
Janssen Pharmaceutica
15
Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents.
Universitat De Barcelona
8
4-Oxo-1,4-dihydro-quinoline-3-carboxamides as BACE-1 inhibitors: synthesis, biological evaluation and docking studies.
Peking University Health Science Center
4
β-Secretase Inhibitors for the Treatment of Alzheimer's Disease and Down's Syndrome.
Therachem Research Medilab (India)
37
ß-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.
F. Hoffmann-La Roche
54
Spirocyclicß-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloidß in a higher species.
Array Biopharma
22
Phenylimino-2H-chromen-3-carboxamide derivatives as novel small molecule inhibitors ofß-secretase (BACE1).
Tehran University of Medical Sciences
17
Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates.
Elan Pharmaceuticals
9
The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches.
Novartis Pharma
14
Discovery of biphenylacetamide-derived inhibitors of BACE1 using de novo structure-based molecular design.
University of Leeds
9
A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.
Novartis Pharma
1
Discovery of alkenylboronic acids as neuroprotective agents affecting multiple biological targets involved in Alzheimer's disease.
Universidad Complutense
10
Novel peptidomimetics as BACE-1 inhibitors: synthesis, molecular modeling, and biological studies.
University of Siena
17
Aminoimidazoles as BACE-1 inhibitors: the challenge to achieve in vivo brain efficacy.
AstraZeneca
61
Self-organizing molecular field analysis on humanß-secretase nonpeptide inhibitors: 5, 5-disubstituted aminohydantoins.
Sichuan University
33
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
Universite£
19
Cyanobacterial peptides as a prototype for the design of potentß-secretase inhibitors and the development of selective chemical probes for other aspartic proteases.
University of Florida
52
Acyl guanidine inhibitors ofß-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis.
Bristol Myers Squibb
23
New aminoimidazoles asß-secretase (BACE-1) inhibitors showing amyloid-ß (Aß) lowering in brain.
AstraZeneca
20
Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation.
Merck Research Laboratories
24
Spirocyclic sulfamides asß-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
Pfizer
14
Structure-based design of highly selectiveß-secretase inhibitors: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.
Purdue University
37
Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease.
Amgen
25
Design and synthesis ofß-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction ofß-amyloid peptides.
AstraZeneca
11
Discovery and optimization of a novel spiropyrrolidine inhibitor ofß-secretase (BACE1) through fragment-based drug design.
Pfizer
31
Design and synthesis of potent, orally efficacious hydroxyethylamine derivedß-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
Amgen
13
Design and preparation of a potent series of hydroxyethylamine containingß-secretase inhibitors that demonstrate robust reduction of centralß-amyloid.
Amgen
44
Conformational restriction approach toß-secretase (BACE1) inhibitors: effect of a cyclopropane ring to induce an alternative binding mode.
Shionogi
6
Structural modifications that alter the P-glycoprotein efflux properties of compounds.
Envoy Therapeutics
18
Design, synthesis, and bioevaluation of benzamides: novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, Aß aggregation, andß-secretase.
Central China Normal University
9
Design and synthesis of potent hydroxyethylamine (HEA) BACE-1 inhibitors carrying prime side 4,5,6,7-tetrahydrobenzazole and 4,5,6,7-tetrahydropyridinoazole templates.
Medivir
4
5-Amino-oxazepine and 5-Amino-thiazepine Compounds as ß-Secretase Antagonists and Methods of Use: Patent Highlight.
TBA
4
BACE Inhibitors: Potential Treatment of Alzheimer's Disease, Dementia, and Related Neurodegenerative Disorders (B): 3-Amino-4-fluoro-1H-isoindol Derivatives: Patent Highlight.
TBA
4
BACE Inhibitors: Potential Treatment of Alzheimer's Disease, Dementia, and Related Neurodegenerative Disorders (A): 5,6-Dihydroimidazo[1,2-a]pyrazin-8-yl-amine Derivatives: Patent Highlight.
TBA
14
Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aß Reduction.
TBA
21
A Potent and Orally Efficacious, Hydroxyethylamine-Based Inhibitor of ß-Secretase.
TBA
17
Structure-based design, synthesis, and biological evaluation of dihydroquinazoline-derived potentß-secretase inhibitors.
Purdue University
29
Synthesis and structure-activity relationship studies of 1,3-disubstituted 2-propanols as BACE-1 inhibitors.
University of South Florida
7
Novel BACE1 inhibitors possessing a 5-nitroisophthalic scaffold at the P2 position.
Kobe Gakuin University
13
Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
University of Waterloo
14
Highly potent macrocyclic BACE-1 inhibitors incorporating a hydroxyethylamine core: design, synthesis and X-ray crystal structures of enzyme inhibitor complexes.
Link£Ping University
57
Discovery of cyclic sulfone hydroxyethylamines as potent and selectiveß-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloidß-peptides.
Novartis Pharma
10
BACE1 Inhibitor Peptides: Can an Infinitely Small k cat Value Turn the Substrate of an Enzyme into Its Inhibitor?
TBA
22
Structure guided P1' modifications of HEA derivedß-secretase inhibitors for the treatment of Alzheimer's disease.
Envoy Therapeutics
31
New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, andß-amyloid-reducing properties.
IQM-CSIC
46
Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor.
Merck Research Laboratories
22
Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases.
Universitat De Barcelona
16
Fragment based drug discovery: practical implementation based on¹¿F NMR spectroscopy.
Amgen
8
Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease.
Zhejiang University
42
Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents.
Elan Pharmaceuticals
40
BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.
Glaxosmithkline
3
Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening.
University of Leeds
18
Di-substituted pyridinyl aminohydantoins as potent and highly selective human beta-secretase (BACE1) inhibitors.
Wyeth Research
5
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
University of Florida
41
Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents.
Elan Pharmaceuticals
8
BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens.
Gyeongsang National University School of Medicine
26
Synthesis, SAR, and X-ray structure of human BACE-1 inhibitors with cyclic urea derivatives.
Lg Life Sciences
35
Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor.
Schering-Plough Research Institute
19
BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs).
Glaxosmithkline
6
BACE1 inhibitors: optimization by replacing the P1' residue with non-acidic moiety.
Kyoto Pharmaceutical University
35
Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket.
Wyeth Research
23
Potent pyrrolidine- and piperidine-based BACE-1 inhibitors.
Schering-Plough Research Institute
10
Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds.
University of Bologna
38
Multi-target-directed ligands to combat neurodegenerative diseases.
University of Bologna
4
Discovery of a novel warhead against beta-secretase through fragment-based lead generation.
AstraZeneca
17
Modeling the binding affinities of beta-secretase inhibitors: application to subsite specificity.
Johnson & Johnson Pharmaceutical Research and Development
13
Calculation of the binding affinity of beta-secretase inhibitors using the linear interaction energy method.
Johnson & Johnson Pharmaceutical Research and Development
8
Secretase targets for Alzheimer's disease: identification and therapeutic potential.
Harvard Medical School
5
The green tea polyphenol (2)-epigallocatechin-3-gallate (EGCG) is not aß-secretase inhibitor.
Beijing Institute of Pharmacology & Toxicology
10
Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design.
Kobe Gakuin University
9
Synthesis of monomeric derivatives to probe memoquin's bivalent interactions.
University of Bologna
47
Structure-activity relationships for naturally occurring coumarins asß-secretase inhibitor.
Kinki University
5
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
Sissa-Isas
13
Discovery of pyrrolidine-basedß-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency.
Merck Research Laboratories
6
On a possible neutral charge state for the catalytic dyad inß-secretase when bound to hydroxyethylene transition state analogue inhibitors.
Universidad De Santiago De Compostela
16
Searching for the Multi-Target-Directed Ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities.
Zhejiang University
8
Rational design and synthesis of aminopiperazinones asß-secretase (BACE) inhibitors.
Research Informatics & Integrative Genomics
16
Design, synthesis, and qualitative structure-activity evaluations of novelß-secretase inhibitors as potential Alzheimer's drug leads.
University of Sharjah
51
Monosubstituted¿-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors ofß-secretase (BACE).
Bristol Myers Squibb
23
Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors.
Bristol Myers Squibb
42
New pyrazolyl and thienyl aminohydantoins as potent BACE1 inhibitors: exploring the S2' region.
Pfizer
36
From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).
Amgen
12
Structure-guided design and synthesis of P1' position 1-phenylcycloalkylamine-derived pentapeptidic BACE1 inhibitors.
Kyoto Pharmaceutical University
14
Multi-target strategy to address Alzheimer's disease: design, synthesis and biological evaluation of new tacrine-based dimers.
Institut F£R Molekulare Physiologie
6
Triazole-linked reduced amide isosteres: an approach for the fragment-based drug discovery of anti-Alzheimer's BACE1 inhibitors.
Virginia Tech
16
Novel non-peptide beta-secretase inhibitors derived from structure-based virtual screening and bioassay.
Singapore Polytechnic
9
Inhibition and structural reliability of prenylated flavones from the stem bark of Morus lhou on β-secretase (BACE-1).
Gyeongsang National University
24
Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors.
Novartis Institutes For Biomedical Research
18
Synthesis and evaluation of arylquinones as BACE1 inhibitors,β-amyloid peptide aggregation inhibitors, and destabilizers of preformed β-amyloid fibrils.
Universidad Complutense
27
Investigation ofa-phenylnorstatine anda-benzylnorstatine as transition state isostere motifs in the search for new BACE-1 inhibitors.
Uppsala University
8
BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides.
University of Pisa
67
Design and synthesis of aminohydantoins as potent and selective humanß-secretase (BACE1) inhibitors with enhanced brain permeability.
Pfizer
17
Molecular docking and structure-activity relationship studies on benzothiazole based non-peptidic BACE-1 inhibitors.
Singapore Polytechnic
19
Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model.
Elan Pharmaceuticals
44
Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region.
Elan Pharmaceuticals
1
Topsentinols, 24-isopropyl steroids from the marine sponge Topsentia sp.
University of Hawaii At Manoa
3
Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy.
University of Bologna
9
Xestosaprols from the Indonesian marine sponge Xestospongia sp.
University of Hawaii At Manoa
135
Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads.
Applied Science University
31
Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors.
Institute of Science and Technology
8
Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity.
Pukyong National University
11
Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads.
Johnson & Johnson Pharmaceutical Research & Development
8
Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at P1' and P4 positions.
Kyoto Pharmaceutical University
42
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization.
Merck Research Laboratories
10
Synthesis and preliminary evaluation of peptidomimetic inhibitors of human beta-secretase.
Peking University
27
Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors.
Wyeth
30
SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition.
Merck Research Laboratories
12
Structure-based design and synthesis of novel P2/P3 modified, non-peptidic beta-secretase (BACE-1) inhibitors.
University of Montreal
8
Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core.
Link£Ping University
6
Biotransformation of isoimperatorin and imperatorin by Glomerella cingulata and beta-secretase inhibitory activity.
Kinki University
11
Discovery of potent BACE-1 inhibitors containing a new hydroxyethylene (HE) scaffold: exploration of P1' alkoxy residues and an aminoethylene (AE) central core.
Stockholm University
18
Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application.
Novartis Institutes For Biomedical Research
21
Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors.
Wyeth Research
48
Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors.
Wyeth Research
5
A conformational constraint improves a beta-secretase inhibitor but for an unexpected reason.
Merck Research Laboratories
28
Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors.
Wyeth Research
4
Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.
Schering-Plough Research Institute
13
Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation.
Schering-Plough Research Institute
17
P2'-truncated BACE-1 inhibitors with a novel hydroxethylene-like core.
Stockholm University
8
Rational design and synthesis of potent dibenzazepine motifs as beta-secretase inhibitors.
University of Sharjah
13
Design and synthesis of BACE-1 inhibitors utilizing a tertiary hydroxyl motif as the transition state mimic.
Uppsala University
3
Prolonged stability by cyclization: Macrocyclic phosphino dipeptide isostere inhibitors of beta-secretase (BACE1).
Technische Universit£T M£Nchen
58
Synthesis and SAR of hydroxyethylamine based phenylcarboxyamides as inhibitors of BACE.
Bristol Myers Squibb
6
Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo.
Novartis Institutes For Biomedical Research
8
Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1.
Merck Research Laboratories
10
Significance of interactions of BACE1-Arg235 with its ligands and design of BACE1 inhibitors with P2 pyridine scaffold.
Kyoto Pharmaceutical University
7
Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
Purdue University
31
Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.
Chinese Academy of Sciences
18
Molecular modeling, synthesis, and activity studies of novel biaryl and fused-ring BACE1 inhibitors.
University of Illinois At Chicago
2
Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors.
Zhejiang University
22
Design, synthesis and SAR of potent statine-based BACE-1 inhibitors: exploration of P1 phenoxy and benzyloxy residues.
LinköPing University
32
Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors.
Schering-Plough Research Institute
6
Tetramic and tetronic acids: an update on new derivatives and biological aspects.
University of Bayreuth
18
Medicinal chemistry-based perspectives on thiophene and its derivatives: exploring structural insights to discover plausible druggable leads.
Birla Institute of Technology and Sciences Pilani Pilani Campus
22
Exploring diverse frontiers: Advancements of bioactive 4-aminoquinoline-based molecular hybrids in targeted therapeutics and beyond.
Universiti Kebangsaan Malaysia
15
Mannich reaction mediated derivatization of chromones and their biological evaluations as putative multipotent ligands for the treatment of Alzheimer's disease.
Central University of Punjab
79
Dual-target inhibitors based on acetylcholinesterase: Novel agents for Alzheimer's disease.
Shenyang Pharmaceutical University
30
Development of novel BACE1 inhibitors with a hydroxyproline-derived N-amidinopyrrolidine scaffold.
Kyoto Pharmaceutical University
24
Progress in the study of anti-Alzheimer's disease activity of pyrimidine-containing bioactive molecules.
Zhengzhou University
23
Promising thiazolidinedione-thiazole based multi-target and neuroprotective hybrids for Alzheimer's disease: Design, synthesis, in-vitro, in-vivo and in-silico studies.
COMSATS University Islamabad
29
Chromenone: An emerging scaffold in anti-Alzheimer drug discovery.
Delhi Pharmaceutical Sciences & Research University
11
Applications of oxetanes in drug discovery and medicinal chemistry.
University of Michigan
12
Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation.
Purdue University
28
BACE-1 inhibitors part 2: identification of hydroxy ethylamines (HEAs) with reduced peptidic character.
Glaxosmithkline
1
Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis.
China Pharmaceutical University
35
Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets.
Wyeth Research
19
Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.
AstraZeneca
12
Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors.
Merck Research Laboratories
30
Design, synthesis, and pharmacological evaluation of indole-piperidine amides as Blood-brain barrier permeable dual cholinesterase and β-secretase inhibitors.
Csir-Indian Institute of Integrative Medicine
30
Lead optimization based design, synthesis, and pharmacological evaluation of quinazoline derivatives as multi-targeting agents for Alzheimer's disease treatment.
Indian Institute of Technology-Banaras Hindu University
19
Design, synthesis, and biological evaluation of some 2-(3-oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-yl)-N-phenylacetamide hybrids as MTDLs for Alzheimer's disease therapy.
Indian Institute of Technology - Banaras Hindu University
7
Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of beta-amyloid.
TBA
25
Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors.
Merck Research Laboratories
12
Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent
Latvian Institute of Organic Synthesis
4
Synthesis and biological evaluation of phosphino dipeptide isostere inhibitor of human beta-secretase (BACE1).
Technische UniversitäT MüNchen
30
Design, synthesis and biological evaluation of novel coumarin derivatives as multifunctional ligands for the treatment of Alzheimer's disease.
Shenyang Pharmaceutical University
23
Discovery of new, highly potent and selective inhibitors of BuChE - design, synthesis, in vitro and in vivo evaluation and crystallography studies.
Jagiellonian University Medical College
33
Recent advance on pleiotropic cholinesterase inhibitors bearing amyloid modulation efficacy.
University of South China
50
Discovery of novel multifunctional ligands targeting GABA transporters, butyrylcholinesterase, β-secretase, and amyloid β aggregation as potential treatment of Alzheimer's disease.
Jagiellonian University Medical College
2
Novel styryl-thiazole hybrids as potential anti-Alzheimer's agents.
University of Athens
30
A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer's disease.
Tehran University of Medical Sciences
65
Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).
University of Aveiro
173
β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.
Univ. Grenoble Alpes
8
Natural spirocyclic alkaloids and polyphenols as multi target dementia leads.
Rmit University
37
Combined MD/QTAIM techniques to evaluate ligand-receptor interactions. Scope and limitations.
Universidad Nacional De San Luis
13
A Quantum Mechanics-Based Method to Predict Intramolecular Hydrogen Bond Formation Reflecting P-glycoprotein Recognition.
Shionogi
7
Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review.
Central University of Rajasthan
27
Recent advancements in chromone as a privileged scaffold towards the development of small molecules for neurodegenerative therapeutics.
Jamia Millia Islamia
101
Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.
Lanzhou University
4
beta-Secretase inhibitors: modification at the P4 position and improvement of inhibitory activity in cultured cells.
Kyoto Pharmaceutical University
10
Cathepsin D inhibitors based on tasiamide B derivatives with cell membrane permeability.
Fudan University
18
Modulating physicochemical properties of tetrahydropyridine-2-amine BACE1 inhibitors with electron-withdrawing groups: A systematic study.
Janssen Research & Development
8
Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres.
Kyoto Pharmaceutical University
11
Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
Ciimar
17
BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: chromene, coumarin and quinoline.
University of The Mediterranean
15
Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors.
Merck
4
Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations.
University of ZüRich
25
Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease.
Central University of Punjab
28
Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
"G. d'Annunzio" University of Chieti-Pescara
7
Small molecules targeting γ-secretase and their potential biological applications.
Shenyang Pharmaceutical University
47
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review.
University of Louisiana At Lafayette
4
Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.
Karolinska Institutet
25
Meroterpenoids produced by fungi: Occurrence, structural diversity, biological activities, and their molecular targets.
Guangzhou University of Chinese Medicine
73
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema.
Kalvista Pharmaceuticals
8
Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress.
Guizhou Medical University
28
A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease.
Indian Institute of Technology (Banaras Hindu University)
15
Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery?
University of Turin
5
Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability.
Kyoto Pharmaceutical University
1
Synthesis of digalactosyl diacylglycerols and their structure-inhibitory activity on human lanosterol synthase.
National Institute of Health Sciences
17
Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360.
TBA
20
Macrocyclic BACE1 inhibitors with hydrophobic cross-linked structures: Optimization of ring size and ring structure.
Kyoto Pharmaceutical University
13
Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease.
Novartis Pharma
37
Efficient evaluation of binding free energy using continuum electrostatics solvation.
University of ZüRich
14
A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid β In Vivo.
Janssen Research & Development
13
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
Lilly Research Laboratories
8
Discovery of Extremely Selective Fused Pyridine-Derived β-Site Amyloid Precursor Protein-Cleaving Enzyme (BACE1) Inhibitors with High In Vivo Efficacy through 10s Loop Interactions.
Shionogi
14
JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate.
Janssen Research & Development
11
From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
University of Barcelona
35
Structure-activity relationship study of hydroxyethylamine isostere and P1' site structure of peptide mimetic BACE1 inhibitors.
Kyoto Pharmaceutical University
9
Inhibition of BACE1 and Amyloid-β Aggregation by Meroterpenoids from the Mushroom
Meiji Pharmaceutical University
4
KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine.
Kyoto Pharmaceutical University
4
Rational design and synthesis of selective BACE-1 inhibitors.
Merck Research Laboratories
1
KMI-008, a novel beta-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides.
Kyoto Pharmaceutical University
45
Discovery of multifunctional anti-Alzheimer's agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and γ-aminobutyric acid transporters.
Jagiellonian University Medical College
6
Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective β-Secretase (BACE1) Inhibitors over BACE2.
Shionogi
10
Green tea catechins as a BACE1 (beta-secretase) inhibitor.
Kyungpook National University
10
Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central Aβ reduction.
Shionogi
8
Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
School of Traditional Chinese Pharmacy
11
Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial.
Janssen Research & Development
38
Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase.
Elan Pharmaceuticals
22
Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6.
University of Barcelona (Ub)
14
The development of a structurally distinct series of BACE1 inhibitors via the (Z)-fluoro-olefin amide bioisosteric replacement.
Amgen
32
Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry.
Endotherm
34
Design, synthesis, and multitargeted profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer's disease.
Indian Institute of Technology (Banaras Hindu University)
32
Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.
Indian Institute of Technology (Banaras Hindu University)
15
Discovery of Orally Active Hydroxyethylamine Based SPPL2a Inhibitors.
Novartis Institutes For Biomedical Research
6
3,3-Difluoro-3,4,5,6-tetrahydropyridin-2-amines: Potent and permeable BACE-1 inhibitors.
Janssen Research & Development
1
Synthesis of morpholine derivatives using the Castagnoli-Cushman reaction as BACE1 inhibitors: Unexpected binding activity of cyclic thioamides.
University of Florence
5
The Medicinal Chemistry in the Era of Machines and Automation: Recent Advances in Continuous Flow Technology.
University of Perugia
12
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
Eli Lilly
32
Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.
Indian Institute of Technology (Banaras Hindu University)
16
Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors.
Bristol Myers Squibb
10
4-Aryl Pyrrolidines as a Novel Class of Orally Efficacious Antimalarial Agents. Part 1: Evaluation of 4-Aryl- N-benzylpyrrolidine-3-carboxamides.
Saint Louis University
9
Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer's disease.
Jining Medical University
4
Tricyclic Inhibitors of β-Secretase and Their Methods of Use for the Treatment of Alzheimer's Disease.
Temple University
13
1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease.
Jagiellonian University Medical College
53
Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships.
Wuhan Institute of Technology
25
Design, synthesis and evaluation of 2-amino-imidazol-4-one derivatives as potent β-site amyloid precursor protein cleaving enzyme 1 (BACE-1) inhibitors.
Nanjing University of Chinese Medicine
11
Cinnamamide: An insight into the pharmacological advances and structure-activity relationships.
National Institute of Pharmaceutical Education and Research (NIPER)
14
Multi-target design strategies for the improved treatment of Alzheimer's disease.
China Pharmaceutical University
22
Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.
TBA
81
Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).
Csir-Central Drug Research Institute
89
New evolutions in the BACE1 inhibitor field from 2014 to 2018.
Janssen Research & Development
19
Design, synthesis, and biological evaluation of novel 4-oxobenzo[d]1,2,3-triazin-benzylpyridinum derivatives as potent anti-Alzheimer agents.
University of Zanjan
6
Synthesis and evaluation of tetrahydroisoquinoline-benzimidazole hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Sun Yat-Sen University
4
Meroterpenoids with BACE1 Inhibitory Activity from the Fruiting Body of
Meiji Pharmaceutical University
16
Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands.
Julius Maximilian University of W£Rzburg
1
Discovery of an Extremely Potent Thiazine-Based β-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose.
TBA
9
Bioactivity-guided identification of flavonoids with cholinesterase and β-amyloid peptide aggregation inhibitory effects from the seeds of Millettia pachycarpa.
Sichuan University
10
Evaluation of a Series of β-Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads.
Janssen Research & Development
6
Synthesis and evaluation of curcumin derivatives toward an inhibitor of beta-site amyloid precursor protein cleaving enzyme 1.
Yamagata University
3
Structure-activity relationship study of BACE1 inhibitors possessing a chelidonic or 2,6-pyridinedicarboxylic scaffold at the P(2) position.
Kobe Gakuin University
5
Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors.
Shiraz University of Medical Sciences
24
Conformational restriction approach to β-secretase (BACE1) inhibitors III: effective investigation of the binding mode by combinational use of X-ray analysis, isothermal titration calorimetry and theoretical calculations.
Hokkaido University
2
Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease.
Vitae Pharmaceuticals
18
Conformational restriction approach to BACE1 inhibitors II: SAR study of the isocytosine derivatives fixed with a cis-cyclopropane ring.
Shionogi
23
Core refinement toward permeable β-secretase (BACE-1) inhibitors with low hERG activity.
AstraZeneca
15
Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2.
TBA
20
Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety.
TBA
34
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
University of Porto
11
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease.
China Pharmaceutical University
22
A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect β-secretase inhibitors.
University of Lille
10
Design, synthesis, X-ray studies, and biological evaluation of novel BACE1 inhibitors with bicyclic isoxazoline carboxamides as the P3 ligand.
Purdue University
19
Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization.
TBA
17
BACE1 Inhibitory Meroterpenoids from Aspergillus terreus.
Huazhong University of Science and Technology
19
Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.
TBA
24
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
Glaxosmithkline
20
Multipotent AChE and BACE-1 inhibitors for the treatment of Alzheimer's disease: Design, synthesis and bio-analysis of 7-amino-1,4-dihydro-2H-isoquilin-3-one derivates.
Central South University
17
Discovery of imidazopyridines containing isoindoline-1,3-dione framework as a new class of BACE1 inhibitors: Design, synthesis and SAR analysis.
University of Tehran
5
Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine β-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation.
Amgen
31
Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.
Pfizer
24
Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors.
University of Pisa
7
Novel multi-target compounds in the quest for new chemotherapies against Alzheimer's disease: An experimental and theoretical study.
The City University of New York (Cuny)
27
Novel tetrahydrocarbazole benzyl pyridine hybrids as potent and selective butryl cholinesterase inhibitors with neuroprotective and β-secretase inhibition activities.
Tehran University of Medical Sciences
1
Isolation, Synthesis, and Antisepsis Effects of a C-Methylcoumarinochromone Isolated from Abronia nana Cell Culture.
Kyungpook National University
19
Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate.
Janssen Pharmaceutica
6
Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer's disease.
Shiraz University of Medical Sciences
23
Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors.
Novartis Institutes For Biomedical Research
16
2-Substituted-thio-N-(4-substituted-thiazol/1H-imidazol-2-yl)acetamides as BACE1 inhibitors: Synthesis, biological evaluation and docking studies.
Peking University Health Science Center
18
Synthesis, docking study and neuroprotective effects of some novel pyrano[3,2-c]chromene derivatives bearing morpholine/phenylpiperazine moiety.
Tehran University of Medical Sciences
6
BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from Sargassum serratifolium.
Pukyong National University
1
Design and synthesis of bicyclic acetals as Beta Secretase (BACE1) inhibitors.
University of Florence
23
Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality.
The Scripps Research Institute
10
Design, synthesis and SAR analysis of potent BACE1 inhibitors: Possible lead drug candidates for Alzheimer's disease.
University of Sharjah
11
Optimization of Hydroxyethylamine Transition State Isosteres as Aspartic Protease Inhibitors by Exploiting Conformational Preferences.
Eli Lilly
8
BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease.
University of Dundee
1
Lodopyridones B and C from a marine sediment-derived bacterium Saccharomonospora sp.
Ewha Womans University
5
Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances.
University of Porto
17
Design, synthesis, and X-ray structural studies of BACE-1 inhibitors containing substituted 2-oxopiperazines as P1'-P2' ligands.
Purdue University
24
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
Dynavax Technologies
25
Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
Shy Therapeutics
19
Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases
Ono Pharmaceutical
16
Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof
Institute of Materia Medica, Chinese Academy of Medical Sciences
108
Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
Incyte
43
Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
Hoffmann-La Roche
13
Pyrazolopyrimidone or Pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof
Shanghai Hengrui Pharmaceutical
35
Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
Merck Sharp & Dohme
96
N-substituted pyrazolo [3,4-D] pyrimidine ketone compound, and preparation process and use thereof
Sun Yat-Sen University
77
Rho kinase inhibitors and methods of use
H. Lee Moffitt Cancer Center and Research Institute
15
1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
AstraZeneca
27
JAK kinase inhibitor compounds for treatment of respiratory disease
Theravance Biopharma R&D Ip
7
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
Abbvie Deutschland
36
3-aryl-2H-pyrazolo[4,3-b]pyridine compounds and their use as AMPA receptor modulators
Janssen Pharmaceutica
72
N2-(2-methoxyphenyl)pyrimidine derivative, method for preparing same, and pharmaceutical composition for cancer prevention or treatment containing same as active ingredient
Korea Research Institute of Chemical Technology
5
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
Zhejiang Dtrm Biopharma
89
Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof
Novartis
220
Sulfoximine substituted quinazolines for pharmaceutical compositions
Evotec Internatonal
247
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
Bristol Myers Squibb
1
Phenyl C-glucoside derivative containing deoxyglucose structure, preparation method and use thereof
Tianjin Institute of Pharmaceutical Research
83
Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
Merck Sharp & Dohme
10
Bifunctional phenolic-choline conjugates as anti-oxidants and acetylcholinesterase inhibitors.
Instituto Superior Técnico
3
Inhibitory effects of thioethers on fatty acid synthase and 3T3-L1 cells.
Graduate University of Chinese Academy of Sciences
15
Discovery of 3,3-di(indolyl)indolin-2-one as a novel scaffold for a-glucosidase inhibitors: In silico studies and SAR predictions
Jishou University
10
Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
Bayer Intellectual Property
20
Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases.
Albert Einstein College of Medicine
2
Molecular basis of cannabinoid CB1 receptor coupling to the G protein heterotrimer Gaiß¿: identification of key CB1 contacts with the C-terminal helix a5 of Gai.
North Carolina Central University
297
Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
Novartis
2
Key mutations alter the cytochrome P450 BM3 conformational landscape and remove inherent substrate bias.
University of Manchester
179
Heterocyclic derivative and pharmaceutical composition comprising the same
Shionogi
9
Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors.
China Pharmaceutical University
8
A simple and efficient synthesis of novel inhibitors of alpha-glucosidase based on benzimidazole skeleton and molecular docking studies.
Recep Tayyip Erdogan University
5
Electrostatic Control of Isoform Selective Inhibitor Binding in Nitric Oxide Synthase.
University of California Irvine
11
Evaluation of Natural and Synthetic 1,4-naphthoquinones as Inhibitors of Monoamine Oxidase.
North-West University
13
Synthesis and biological evaluation of kojic acid derivatives containing 1,2,4-triazole as potent tyrosinase inhibitors.
Hunan University of Science and Technology
3
Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
Abbvie Deutschland
5
Synthesis of Novel Hybrids Inspired from Bromopyrrole Alkaloids Inhibiting MMP-2 and -12 as Antineoplastic Agents.
University of Kwazulu-Nata
8
Synthesis, Biological Evaluation, and Molecular Simulation of Chalcones and Aurones as Selective MAO-B Inhibitors.
Pontificia Universidad Catolica De Chile
10
Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
Rhizen Pharmaceuticals
1
Identification and Co-complex Structure of a New S. pyogenes SpeB Small Molecule Inhibitor.
The Scripps Research Institute
563
Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
Merck Sharp & Dohme
13
Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
High Point Pharmaceuticals
151
Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
Dermira (Canada)
10
Functionalization of ß-Caryophyllene Generates Novel Polypharmacology in the Endocannabinoid System.
University of Bern
1
Interactive binding between the substrate and allosteric sites of carbamoyl-phosphate synthetase.
Pennsylvania State University
3
Triazaspirodimethoxybenzoyls as selective inhibitors of mycobacterial lipoamide dehydrogenase .
Weill Cornell Medical College
9
Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems.
University of Colorado Denver
1
Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against "nucleotide-competing reverse transcriptase inhibitors".
Mcgill University
4
Inhibition studies on the membrane-associated phospholipase A2 in vitro and prostaglandin E2 production in vivo of the macrophage-like P388D1 cell. Effects of manoalide, 7,7-dimethyl-5,8-eicosadienoic acid, and p-bromophenacyl bromide.
University of California San Diego
5
2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation.
AstraZeneca
25
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.
Universit&Aagrov
5
Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors.
University of Michigan
27
Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.
Nih
2
Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.
Mcgill University
42
Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
University of Toronto
12
Identification and characterization of the leech CNS cannabinoid receptor: coupling to nitric oxide release.
State University of New York At Old Westbury
12
In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
Hoechst Marion Roussel
19
The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.
Pfizer
37
1H-1,2,4-triazol-3-yl-anilines: novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2.
Chemdiv
10
Characterization of recombinant human serotonin 5HT1A receptors expressed in Chinese hamster ovary cells. [3H]spiperone discriminates between the G-protein-coupled and -uncoupled forms.
University of Canterbury
15
Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization.
Cnrs
8
Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines.
Washington University
13
In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.
Merck Research Laboratories
2
5-Hydroxytryptamine receptors with a 5-HT6 receptor-like profile stimulating adenylyl cyclase activity in pig caudate membranes.
Sandoz Pharma
5
Molecular, functional, and pharmacological characterization of the metabotropic glutamate receptor type 5 splice variants: comparison with mGluR1.
Cnrs Ccipe
20
Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY.
Synaptic Pharmaceutical
6
Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor.
Bristol Myers Squibb
6
Characterization of somatostatin receptor subtypes controlling rat gastric acid and pancreatic amylase release.
Tulane University
11
Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum.
University of California
2
Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.
Wyeth Laboratories
10
Quantitative autoradiography of serotonin uptake sites in rat brain using [3H]cyanoimipramine.
Veterans Administration Medical Center
7
Binding properties of the C-terminal domain of VIAF.
The Burnham Institute For Medical Research
18
Selective mapping of chemical space for Pseudomonas aeruginosa deacetylase LpxC inhibitory potential.
National Institute of Pharmaceutical Education and Research
21
Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors.
Pfizer
17
Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity.
Veterans Affairs Medical Center
123
RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS
Trustees of Tufts College
5
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.
The Scripps Research Institute
14
Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.
Boehringer Ingelheim Pharmaceuticals
19
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Bristol Myers Squibb
34
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3.
Bristol Myers Squibb
20
Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.
Glaxosmithkline
24
Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.
Glaxosmithkline
8
Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.
Bristol Myers Squibb